You are about to leave the Clinical Value website now.

Cancel

PIVKA-II

19 August 2024

Pioneering Innovations in HCC Detection for Enhance Patient Outcomes – Chang Gung Memorial Hospital

12 April 2024

Urgent Global Need for PIVKA-II and AFP-L3 Measurements for Surveillance and Management of Hepatocellular Carcinoma

13 February 2024

The Pursuit for Better Patient Outcomes – Innovating HCC Management at Siriraj Hospital

18 September 2023

Advancing Liver Health Ecosystem for Improve Patient Outcomes: A Hong Kong Perspective

In this interview with Prof Yuen, Chief of Division of Gastroenterology and Hepatology in the University of Hong Kong, explore Hong Kong's current liver health ecosystem,…

READ MORE
23 June 2023

Leading the Way for HCC Surveillance and Diagnosis: Prof. Henry LY Chan

In this video, Prof Henry LY Chan, Deputy Chief Manager at Union Hospital Hong Kong, discusses how PIVKA-II can complement AFP and Ultrasound in assisting clinicians…

READ MORE
19 June 2023

Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis

This study aimed to investigate the role of serum PIVKA-II and alpha-fetoprotein in predicting HCC and mortality in cirrhotic CHB patients at virological remission following NA…

READ MORE
19 June 2023

Do combined assays of serum AFP, AFP-L3, DCP, GP73, and DKK-1 efficiently improve the clinical values of biomarkers in decision-making for hepatocellular carcinoma? A meta-analysis

This meta-analysis aims to provide insight on the efficacy of using combined biomarkers, AFP, AFP-L3, DCP, DKK-1, and GP73, for clinical decision-making for patients with HCC.…

READ MORE
19 June 2023

The prognostic values of serum markers in hepatocellular carcinoma after invasive therapies based on real-world data

The purpose of this study is to evaluate the prognostic values of serum markers in HCC, with retrospective data. Li B, Liu A, Wen Y, Yang…

READ MORE
19 June 2023

The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients

This study aims to investigate the diagnostic role of PIVKA-II alone or in combination with AFP in Chinese HCC patients. Xu F, Zhang L, He W,…

READ MORE
19 April 2023

Clinical Utility of Protein Induced by Vitamin K Absence-II in Patients with Hepatocellular Carcinoma

This study aimed to assess the clinical utility of PIVKA-II in addition to AFP in patients with HCC. Bhatti ABHH, Naz K, Abbas G, Khan NY,…

READ MORE
12 April 2023

PIVKA-II: Confidence in HCC surveillance and diagnosis: Prof. Ming-Lung Yu

In this video, Prof Ming-Lung Yu, Chair Professor of Hepatology at Kaohsiung University Medical Hospital, discusses how PIVKA-II can complement AFP and Ultrasound in assisting clinicians…

READ MORE
17 March 2023

Utility of Combining PIVKA-II and AFP in the Surveillance and Monitoring of Hepatocellular Carcinoma in the Asia-Pacific Region

A panel of 17 experts from Asia-Pacific, gathered to discuss and reach a consensus on the clinical usefulness and value of PIVKA-II for the surveillance and…

READ MORE
17 March 2023

Evaluation of the diagnostic accuracy of des-gamma-carboxy prothrombin and alpha-fetoprotein alone or in combination for hepatocellular carcinoma: A systematic review and meta-analysis

This article aims to clarify the diagnostic value of DCP (PIVKA-II) and AFP in patients with different risk of HCC development (etiology, ethnicity, and various stages…

READ MORE
17 March 2023

A meta-analysis and of clinical values of 11 blood biomarkers, such as AFP, DCP, and GP73 for diagnosis of hepatocellular carcinoma

This study reanalyzes the related studies of 11 blood biomarkers of HCC, and compares the diagnostic value of these biomarkers for HCC systematically. Pang BY, Leng…

READ MORE
14 March 2023

Surveillance of Hepatocellular Cancer Among Hepatitis B and Cirrhosis Patients Using Protein Induced by Vitamin K Absence-II (PIVKA-II): A Cost-Utility Analysis for Hong Kong as an Example of Endemic Regions

This study evaluates the cost-effectiveness of serological tests or ultrasound alone versus their joint use with or without multivariate index algorithm for HCC screening in chronic…

READ MORE
14 March 2023

Biomarkers for the Early Detection of Hepatocellular Carcinoma

This review highlights promising candidate biomarkers and biomarker panels that have completed phase II evaluation for the early detection of HCC. Parikh ND, Mehta AS, Singal…

READ MORE
14 March 2023

Cost-effectiveness Analysis of GAAD algorithm on Hepatocellular Carcinoma Screening in Patients with Chronic Hepatitis B in China

This study evaluates the cost-effectiveness of serological tests or ultrasound alone versus their joint use with or without multivariate index algorithm for HCC screening in chronic…

READ MORE
14 March 2023

Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

These latest guidelines recommend evidence-based management of HCC and are considered suitable for universal use in the Asia-Pacific region, which has a diversity of medical environments.…

READ MORE
14 March 2023

Impact of PIVKA-II in diagnosis of hepatocellular carcinoma

This study was designed to investigate the potential role of PIVKA-II as a diagnostic, non-invasive marker for HCC at its early stages and to assess its…

READ MORE
14 March 2023

Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma

This study aims to determine the cutoff values and to compare the diagnostic role of alpha-fetoprotein (AFP) and prothrombin induced by vitamin K absence-II (PIVKA-II) in…

READ MORE
14 March 2023

Diagnostic value of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage HBV related hepatocellular carcinoma

This study aims to evaluate the diagnostic efficacy of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage hepatitis virus B…

READ MORE
13 March 2023

Protein induced by vitamin K absence or antagonist-II versus alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: A systematic review with meta-analysis

PIVKA-II has been extensively studied as a biomarker in HCC. However, its diagnostic capability varies across HCC studies. This study aimed to compare the performance of…

READ MORE
13 March 2023

Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA

This study aims to determine the clinical value of serum Prothrombin induced by vitamin K absence-II (PIVKA-II) in early hepatocellular carcinoma (HCC), and to explore its…

READ MORE
13 March 2023

Leading the Way for HCC Surveillance and Diagnosis: Dr Bao Toan Nguyen

In this video, Dr Bao Toan Nguyen from MEDIC-LAB Ho Chi Minh discusses how PIVKA-II can complement AFP in assisting clinicians in the early detection and…

READ MORE
9 December 2022

Performance evaluation of the Elecsys PIVKA-II and Elecsys AFP assays for hepatocellular carcinoma diagnosis

Prothrombin induced by vitamin K absence-II (PIVKA-II) is a serum biomarker linked to hepatocellular carcinoma (HCC), showing superiority to alpha-fetoprotein (AFP) for early disease detection. This…

READ MORE
9 December 2022

Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case-Control Study

This study systematically evaluates biomarkers mentioned in international guidelines and peer-reviewed literature for HCC surveillance and diagnosis, in order to identify combinations of biomarkers that display…

READ MORE
9 December 2022

Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma

Prothrombin induced by vitamin K absence-II (PIVKA-II) was reported as a diagnosis and prognosis marker for hepatocellular carcinoma (HCC). This prospective study aims to comparatively verify…

READ MORE
9 December 2022

Analytical performance and method comparison of the Elecsys PIVKA-II immunoassay as an aid in diagnosis of hepatocellular carcinoma (HCC)

This study evaluates the analytical performance of the Elecsys PIVKA-II immunoassay to aid in HCC diagnosis, establish method-specific reference ranges in healthy individuals, and perform a…

READ MORE

Be the first to receive updates, event opportunities, and thought leadership insights.